Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

08:43
10/10/16
10/10
08:43
10/10/16
08:43

Merck 'steals the show' at ESMO with Keytruda data, says Leerink

Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.

TODAY'S FREE FLY STORIES

MRK

Merck

$58.66

1.06 (1.84%)

06:46
01/16/18
01/16
06:46
01/16/18
06:46
Hot Stocks
Merck: Phase 3 KEYNOTE-189 trial met dual primary endpoints »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 25

    Mar

  • 03

    Apr

  • 23

    Oct

SPX

S&P 500

06:45
01/16/18
01/16
06:45
01/16/18
06:45
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

, DDAIF

Daimler AG

$90.25

1.44 (1.62%)

06:41
01/16/18
01/16
06:41
01/16/18
06:41
Periodicals
Fiat Chrysler, Daimler warn over Europe's emissions targets, FT says »

Fiat Chrysler (FCAU) and…

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

DDAIF

Daimler AG

$90.25

1.44 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAC

GAP Airports

$102.12

0.45 (0.44%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Earnings
GAP Airports sees FY18 total revenue growth 13%, plus or minus 1% »

FY18 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.76

-0.26 (-1.37%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Hot Stocks
GE Capital to fund contributions, suspend dividend to GE for forseeable future »

GE Capital to fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

K

Kellogg

$64.69

-1.29 (-1.96%)

, CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Recommendations
Kellogg, Campbell Soup analyst commentary  »

Kellogg added to U.S.…

K

Kellogg

$64.69

-1.29 (-1.96%)

CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

GE

General Electric

$18.76

-0.26 (-1.37%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Hot Stocks
GE to take $6.2B charge in Q4 on insurance operations »

GE announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

06:37
01/16/18
01/16
06:37
01/16/18
06:37
Upgrade
Campbell Soup rating change  »

Campbell Soup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$24.01

0.63 (2.69%)

06:36
01/16/18
01/16
06:36
01/16/18
06:36
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$126.96

1.52 (1.21%)

06:35
01/16/18
01/16
06:35
01/16/18
06:35
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$27.53

0.38 (1.40%)

06:34
01/16/18
01/16
06:34
01/16/18
06:34
Periodicals
Airbus prepared to shut down production of A380 superjumbo, FT reports »

Airbus is ready to shut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$34.63

2.54 (7.92%)

06:34
01/16/18
01/16
06:34
01/16/18
06:34
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.81

1.47 (8.48%)

06:33
01/16/18
01/16
06:33
01/16/18
06:33
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$36.73

0.53 (1.46%)

06:32
01/16/18
01/16
06:32
01/16/18
06:32
Upgrade
21st Century Fox rating change  »

21st Century Fox upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

DUST

Direxion Daily Gold Miners Bear 3X ETF

$21.30

-1.89 (-8.15%)

06:32
01/16/18
01/16
06:32
01/16/18
06:32
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SP

SP Plus Corp.

$38.00

0.2 (0.53%)

06:31
01/16/18
01/16
06:31
01/16/18
06:31
Hot Stocks
SP Plus Corp. sells joint venture interest in Parkmobile, sees Q1 gain »

SP Plus Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$47.10

-4.42 (-8.58%)

06:31
01/16/18
01/16
06:31
01/16/18
06:31
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$25.85

0.01 (0.04%)

06:30
01/16/18
01/16
06:30
01/16/18
06:30
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

$65.35

1.06 (1.65%)

06:29
01/16/18
01/16
06:29
01/16/18
06:29
Downgrade
Dolby rating change  »

Dolby downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$144.75

-0.25 (-0.17%)

06:29
01/16/18
01/16
06:29
01/16/18
06:29
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$76.84

1.28 (1.69%)

06:28
01/16/18
01/16
06:28
01/16/18
06:28
Periodicals
Citi results likely 'overwhelmed' by $20B charge due to tax overhaul, WSJ says »

Citigroup's results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

JPM

JPMorgan

$112.67

1.83 (1.65%)

06:28
01/16/18
01/16
06:28
01/16/18
06:28
Hot Stocks
JPMorgan reports December net credit losses 2.43% vs. 2.36% last month »

Reports December 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$4.74

0.01 (0.21%)

06:27
01/16/18
01/16
06:27
01/16/18
06:27
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNV

Innovus Pharmaceuticals

06:27
01/16/18
01/16
06:27
01/16/18
06:27
Hot Stocks
Innovus Pharmaceuticals' hemorrhoid drug Xyralid approved in Canada »

Innovus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$138.19

-0.02 (-0.01%)

06:26
01/16/18
01/16
06:26
01/16/18
06:26
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.